Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: EA Should Spend Its “Funding Overhang” on Curing Infectious Diseases, published by joshcmorrison on November 17, 2021 on The Effective Altruism Forum.
Intro
Tl;dr
Epistemic Status
Big Problem
Good Solutions
Advanced Market Commitments
Challenge Studies
Other
Good Timing
Good for the EA Movement
Diversification
Reputation
Catastrophic Risk
Good Arguments Against
No Rigorous Methodology
Long-Term Disease Burden Could Be Much Lower
1Day Sooner May Have been Wrong About COVID Challenge
Vaccines May Be Very Difficult to Develop
Vaccines Aren’t a Silver Bullet
Gates and Wellcome Already Fund This
Next Steps
Intro
There has been much discussion in the EA community lately of a “funding overhang” where there is more effective altruist money to spend than EA uses to spend it on.
As a nonprofit employee of 1Day Sooner whose salary is largely paid by various members of the EA community, the prospect of a funding overhang sounds too good to be true, but insofar as it does exist, I’d like to argue that a fair amount of this decade’s portion should be spent developing and deploying vaccines against infectious diseases.
Millions of deaths each year are caused by tuberculosis (1.4M), Group A Strep (500K), malaria (400K), influenza (300K), hepatitis C (300K), shigella (200K), and respiratory syncytial virus (160K). On certain reasonable assumptions, I’d argue they can absorb billions of dollars in GiveWell-charity equivalent funding over the next ten years. Beyond the object-level of saving millions of lives, developing effective vaccines to major diseases would benefit pandemic preparedness and EA’s political reputation in a way that could reduce existential risks long-term.
My expertise on vaccine development is at best incomplete, and I am biased because 1Day Sooner is raising money to work in this area. But the scale of the problem is large, multiple reasonable strategies exist to help address it, the timing is opportune, and the approach usefully diversifies EA funding strategies while complementing other long-term EA goals.
Tl;dr: If EA’s investing $10 billion in vaccination over the next ten years could save the equivalent of 3-5 years of disease burden of a disease like tuberculosis, it would represent a cost per disability-adjusted-life-year (DALY) saved of roughly $50-$85 (on par with GiveWell top charities). There are plausible mechanisms available to accomplish this, such as advanced market commitments, challenge studies, systems immunology research, and subsidizing mRNA vaccine manufacturing capacity. The effective altruism movement should quickly begin investigating this area more thoroughly and consider developing funding mechanisms commensurate with the scale of the opportunity.
Epistemic Status:I feel this makes a decent but simplistic default case that merits mild confidence in the absence of refutation (which I encourage people to do so as to sharpen the analysis).
Big Problem: Infectious disease is a big enough problem that a number of GiveWell’s top charities (e.g. Against Malaria Foundation and the END Fund) focus on mitigating its impact. Developing and deploying vaccines can dramatically reduce disease incidence in the long-run.
To give a sense of scale, here are the DALY’s lost annually to some vaccine-preventable diseases.
Per this workshop on Group A Strep, an accelerated vaccine development schedule for a disease might typically take about eight years with a further eight years for global deployment. It estimates a more traditional development process at 13 years and deployment at 15-20 years thereafter.
If GiveWell charities buy a DALY at $80, it would be worth it to invest (for example) $3.2 billion to eliminate a single year of tuberculosis disease burden.
Good Solutions: While I have not done comprehensive research into potential strategies to deploy fu...